Building a sterile manufacturing facility at Daewoong Bio Plant 3
Establishing a foundation for commercializing obesity treatment patches and more

Daewoong Pharmaceutical is building production infrastructure to commercialize microneedle medicines, a next-generation drug delivery technology. The company aims to complete Good Manufacturing Practice (GMP) approval for the dedicated manufacturing facility by the first half of 2027.


Daewoong Pharmaceutical said on Wednesday that it is building a dedicated sterile facility for manufacturing microneedle drugs for clinical trials at Plant 3 of Daewoong Bio. The move is intended to secure a stable supply of clinical trial drugs and enable a transition to commercial production in the future.


Artist's rendering of the dedicated sterile manufacturing facility for microneedles at Daewoong Bio's 3rd Plant in Hwaseong, Gyeonggi Province. Daewoong Pharmaceutical.

Artist's rendering of the dedicated sterile manufacturing facility for microneedles at Daewoong Bio's 3rd Plant in Hwaseong, Gyeonggi Province. Daewoong Pharmaceutical.

View original image

Microneedles deliver drugs through a patch with tiny needles that is applied to the skin. They can reduce the burden of administration compared with conventional injections and improve convenience for patients. Daewoong Pharmaceutical plans to expand infrastructure optimized for producing next-generation patch-based medicines, including DWRX5003, a candidate for treating obesity and diabetes that contains semaglutide, based on Daewoong Therapeutics' microneedle technology, "Clofarm."


To that end, the company is introducing a sterile manufacturing process and an automated production system tailored to the characteristics of microneedles. It said that precision automated dispensing technology, which distributes drugs evenly into micro-molds, and pressure-drying technology, which concentrates the drug at the tips of the needles, have improved the uniformity of drug content and the reproducibility of product quality.


A robotic transfer system will be used throughout the entire process, from precision dispensing and pressure drying to product packaging. This is intended to minimize direct worker involvement and reduce the risk of cross-contamination and human error. The company is also establishing contamination-prevention systems, including a sterile barrier system and air filtration equipment. In addition, it plans to strengthen its quality-control capabilities by introducing real-time monitoring and an electronic record-tracking system.



"We will build sterile automated manufacturing infrastructure without a hitch and establish a solid foundation for the global commercialization of our next-generation pipeline," said Lee Seung-ha, head of Daewoong Pharmaceutical's Production Division.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing